Breaking News

CTC, Recipharm Partner on Joint Phase I Services

June 23, 2014

Aims to provide more efficient Phase I studies

CTC (Clinical Trial Consultants) and Recipharm have entered into a collaboration to offer complete packages for Phase I studies including development and manufacture of clinical trial material. The partnership will also cover planning, performing and evaluation of the clinical trial.
Maria Lundberg, general manager Recipharm Pharmaceutical Development, said, “I am delighted about this collaboration. CTC has excellent experience in clinical trials and a unique Phase I unit at Uppsala University Hospital (Akademiska Sjukhuset). Together we will be able to offer customers faster and more cost-efficient Phase I studies. We can from now on take full responsibility for coordination of the work which might be valuable to small virtual companies.”
Bengt Dahlström, chief executive officer of CTC Clinical Trial said, “I am very pleased that CTC and Recipharm now can offer a joint service which will benefit from the companies longstanding expertise in contract development and manufacturing and early clinical research. This systematic integrated approach will help our clients to shorten project time-lines and at the same time obtain more information on the desirable properties of the drug formulation. Adaptive design is a key element in getting more information from each study and modifying the design based on the data obtained all within a single protocol.”

Related Contract Manufacturing:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research